Payment overview · 2025
General Payments
$335.46
17 reported records · 11 companies
Healthcare provider profile · identity verified
Craig Alan Greenman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1982960373
Verified facts
What the public records show
CMS Open Payments records show Craig Alan Greenman, MD received $335.46 in general payments during 2025 across 17 reported records.
Sumitomo Pharma America, Inc. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.23 | 26.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.68 | 17.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.47 | 17.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.84 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.55 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.67 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.34 | 4.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.26 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.61 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.51 | 4.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.30 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.46 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.23 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $57.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 350 | 106 |
| Losartan Potassium | Losartan Potassium | 340 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 67 |
| Nifedipine Er | Nifedipine | 190 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 187 | 50 |
| Lisinopril | Lisinopril | 165 | 50 |
| Trazodone Hcl | Trazodone Hcl | 146 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 39 |
| Tramadol Hcl | Tramadol Hcl | 134 | 45 |
| Gabapentin | Gabapentin | 132 | 49 |
| Metformin Hcl | Metformin Hcl | 130 | 42 |
| Carvedilol | Carvedilol | 123 | 39 |
| Alprazolam | Alprazolam | 122 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 40 |
| Valsartan | Valsartan | 114 | 32 |
| Metformin Hcl Er | Metformin Hcl | 113 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 33 |
| Buspirone Hcl | Buspirone Hcl | 111 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 28 |
| Sertraline Hcl | Sertraline Hcl | 104 | 26 |
| Omeprazole | Omeprazole | 98 | 36 |
| Furosemide | Furosemide | 92 | 30 |
| Ozempic | Semaglutide | 92 | 18 |
| Montelukast Sodium | Montelukast Sodium | 89 | 30 |
| Clonazepam | Clonazepam | 87 | 18 |
| Pregabalin | Pregabalin | 78 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 26 |
| Eliquis | Apixaban | 75 | 14 |
| Spironolactone | Spironolactone | 75 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 27 |
| Allopurinol | Allopurinol | 72 | 21 |
| Potassium Chloride | Potassium Chloride | 70 | 22 |
| Mounjaro | Tirzepatide | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 19 |
| Trulicity | Dulaglutide | 63 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 16 |
| Meloxicam | Meloxicam | 58 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 25 |
| Synthroid | Levothyroxine Sodium | 53 | 16 |
| Diazepam | Diazepam | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | 18 |
| Labetalol Hcl | Labetalol Hcl | 50 | 14 |
| Temazepam | Temazepam | 50 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 11 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 19 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 13 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Cefdinir | Cefdinir | 25 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.46 · 17 records | Sumitomo Pharma America, Inc. | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, CREON, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, GEMTESA, KISUNLA, Korlym, LINZESS, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error